This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific (BSX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 4.76% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?
by Zacks Equity Research
Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TG Therapeutics (TGTX) Soars 18.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
by Zacks Equity Research
The FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for ublituximab for relapsing multiple sclerosis. Shares fell 14.5% following the announcement.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 15% and 4.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will TG Therapeutics (TGTX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down
by Zacks Equity Research
TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.
TG Therapeutics (TGTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Q4 Earnings Miss Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -62.50% and 1.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Moves 17.7% Higher: Will This Strength Last?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TG Therapeutics (TGTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -16.07% and -37.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About TG Therapeutics (TGTX) Stock We Don't?
by Aditi Saraogi
Investors need to pay close attention to for TG Therapeutics (TGTX) stock based on the movements in the options market lately.
TG Therapeutics (TGTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -22.92% and -58.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: TG Therapeutics, Alpha Metallurgical Resources and Ambarella
by Zacks Equity Research
Zacks.com featured highlights include: TG Therapeutics, Alpha Metallurgical Resources and Ambarella
3 Stocks to Watch Out For Solid Earnings Acceleration
by Tirthankar Chakraborty
Keep an eye on stocks like TG Therapeutics (TGTX), Alpha Metallurgical Resources (AMR) & Ambarella (AMBA) for stellar earnings acceleration at the moment.
Zacks.com featured highlights include: Western Digital Corp, TG Therapeutics, DocuSign, Kaiser Aluminum Corp and United Insurance Holdings
by Zacks Equity Research
Zacks.com featured highlights include: Western Digital Corp, TG Therapeutics, DocuSign, Kaiser Aluminum Corp and United Insurance Holdings
5 Stocks to Watch Out For Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Western Digital (WDC), DocuSign (DOCU) & Kaiser Aluminum (KALU) are some of the stocks that at present are showing superb earnings acceleration, which may lead to an uptick in the stock price.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
TG Therapeutics (TGTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -32.69% and -20.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Q1 Earnings on May 10: MRVI, TGTX & More
by Urmimala Biswas
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Earnings Preview: TG Therapeutics (TGTX) Q1 Earnings Expected to Decline
by Zacks Equity Research
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in TG Therapeutics (TGTX): Can Its 6.7% Jump Turn into More Strength?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Company News for Mar 3, 2021
by Zacks Equity Research
Companies in The News Are: KSS,AZO,TGTX,KTB